ACCE Biotech Catalysts vs ACCE Smart Money

Head-to-head: performance, risk profile, and constituent overlap between two ACCE indices.

Binary catalyst pipeline — FDA approvals, late-stage trial readouts, and M&A targets. High conviction names with visible catalysts.

ACCE Smart Money →

Stocks being accumulated by multiple quality institutional managers across our curated 13F universe. Rebalanced quarterly after 13F filing deadlines (Feb / May / Aug / Nov).

Performance windows

Period	ACCE Biotech Catalysts	ACCE Smart Money	Spread
1M	-2.1%	+0.3%	-2.4%
3M	-10.4%	+0.3%	-10.7%
YTD	-5.7%	+0.3%	-6.1%
1Y	-5.7%	+0.3%	-6.1%
3Y	-5.7%	+0.3%	-6.1%
5Y	-5.7%	+0.3%	-6.1%
Inception	-5.7%	+0.3%	-6.1%

ACCE Biotech Catalysts - risk

Volatility 30d+27.1%

Volatility 90d+26.1%

Sharpe 90d-0.67

Max drawdown-13.4%

Beta vs SPY0.94

ACCE Smart Money - risk

Volatility 30d-

Volatility 90d-

Sharpe 90d-

Max drawdown-0.8%

Beta vs SPY-

Constituent overlap

1 stock held by both indices (out of 7 and 35)

Top sectors - ACCE Biotech Catalysts

Healthcare100.0%

Top sectors - ACCE Smart Money

Technology31.4%

Financial Services22.9%

Communication Services17.1%

Consumer Cyclical11.4%

Healthcare5.7%

Consumer Defensive5.7%

ACCE Verdict

## Verdict

ACCE Biotech Catalysts has underperformed its benchmark by 11.12 percentage points since inception, posting a -4.19% return against the benchmark's 6.93% gain. That gap is the defining fact of this comparison.

The risk profile of Biotech Catalysts is punishing for that level of return: 90-day volatility of 25.97%, a Sharpe of -0.52, and a maximum drawdown of -13.41% mean investors are absorbing significant turbulence with negative risk-adjusted compensation. Smart Money carries no comparable live risk data yet, so a direct metric-to-metric comparison is not possible.

The two indices share little structural overlap. Biotech Catalysts concentrates on binary-event names, FDA calendars, and M&A speculation. Smart Money is built on aggregated institutional conviction drawn from 13F filings, rebalanced quarterly, and skews toward names where multiple quality managers are adding exposure simultaneously.

Biotech Catalysts suits an investor who wants explicit catalyst exposure and accepts that binary readouts produce binary outcomes, including the drawdowns visible in the current data. Smart Money, once its track record develops, targets investors who prefer to follow institutional accumulation patterns rather than bet on trial outcomes. With Biotech Catalysts currently underwater versus benchmark and Smart Money too early-stage to evaluate, neither index presents a clean entry case on performance alone right now.